Cargando…
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
BACKGROUND: Chronic hepatitis C virus (HCV) infection is a significant medical burden in China, affecting more than 10 million persons. In clinical trials and real-world settings, treatment with ledipasvir/sofosbuvir in patients with genotype 1 HCV infection resulted in high sustained virologic resp...
Autores principales: | Wei, Lai, Xie, Qing, Hou, Jin Lin, Tang, Hong, Ning, Qin, Cheng, Jun, Nan, Yuemin, Zhang, Lunli, Li, Jun, Jiang, Jianning, McNabb, Brian, Zhang, Fangqiu, Camus, Gregory, Mo, Hongmei, Osinusi, Anu, Brainard, Diana M., Gong, Guozhong, Mou, Zhuangbo, Wu, Shanming, Wang, Guiqiang, Hu, Peng, Gao, Yanhang, Jia, Jidong, Duan, Zhongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904238/ https://www.ncbi.nlm.nih.gov/pubmed/29637511 http://dx.doi.org/10.1007/s12072-018-9856-z |
Ejemplares similares
-
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019) -
Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018) -
Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017) -
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017) -
Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)